Populations from two medieval sites in Central Poland, Stary Brześć Kujawski-4 (SBK-4) and Gruczno, represented high level of lactase persistence (LP) as followed by the LCT-13910*T allele's presence (0.86 and 0.82, respectively). It was twice as high as in contemporaneous Cedynia (0.4) and Śródka (0.43), both located outside the region, higher than in modern inhabitants of Poland (0.51) and almost as high as in modern Swedish population (0.9). In an attempt to explain the observed differences its frequency changes in time were followed between the Middle Neolithic and the Late Middle Ages in successive dairying populations on a relatively small area (radius ∼60km) containing the two sites. The introduction of the T allele to Kuyavia 7.4 Ka BP by dairying LBK people is not likely, as suggested by the obtained data. It has not been found in any of Neolithic samples dated between 6.3 and 4.5 Ka BP. The identified frequency profile indicates that both the introduction and the beginning of selection could have taken place approx. 4 millennia after first LBK people arrived in the region, shifting the value of LP frequency from 0 to more than 0.8 during less than 130 generations. We hypothesize that the selection process of the T allele was rather rapid, starting just after its introduction into already milking populations and operated via high rates of fertility and mortality on children after weaning through life-threatening conditions, favoring lactose-tolerant individuals. Facing the lack of the T allele in people living on two great European Neolithization routes, the Danubian and Mediterranean ones, and based on its high frequency in northern Iberia, its presence in Scandinavia and estimated occurrence in Central Poland, we propose an alternative Northern Route of its spreading as very likely. None of the successfully identified nuclear alleles turned out to be deltaF508 CFTR.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390234 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122384 | PLOS |
Nat Med
January 2025
Data Science, Novo Nordisk A/S, Søborg, Denmark.
Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 (n = 1,311) and STEP 2 (n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways.
View Article and Find Full Text PDFNeurology
December 2024
From the Departments of Neurology (R.R., K.A.O.N., R.K., A.S., L.B.K.), Population Health (R.K.), and Radiology (J.T.L.), New York University Grossman School of Medicine, New York; Department of Neurology (R.R.), Weill Cornell Medical Center, New York; Department of Biostatistics (R.A.B.), New York University School of Global Public Health, New York; icometrix (T.B.), Leuven, Belgium; Department of Pediatrics (M.M.-S.), Baylor College of Medicine, Houston, TX; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital (M.M.-S.), Houston; and Department of Pediatrics (H.D.M., M.W.), University of Utah, Salt Lake City.
Background And Objectives: Accumulating evidence points to worse clinical outcomes among adults with multiple sclerosis (MS) belonging to minority or poverty-affected groups. By contrast, little is known about the outcomes of these populations with pediatric-onset MS (POMS). Individuals with POMS represent 5% of the MS population and are more racially diverse yet have been understudied regarding socioeconomic environment or characteristics.
View Article and Find Full Text PDFNeurology
December 2024
From the Department of Neurology (E. Wilson), Cincinnati Children's Hospital, OH; Department of Neurology (E. Wilson, M.P.G., L.A.B.), Boston Children's Hospital, MA; Department of Pediatric Neurology (E. Wilson, K.C., T.C.), Massachusetts General Hospital, Boston; Department of Pediatrics (H.D.M., B.J.B., M.W., T.C.C., J.W.R.), University of Utah, Salt Lake City; Department of Neurology (M. Rodriguez, J.-M.T.), Mayo Clinic, Rochester, MN; Department of Neurology (M. Rensel, A.W.A.), Cleveland Clinic, OH; Department of Neurology (L.B.K.), New York University Medical Center, NY; Department of Neurology (T.E.L., K.S.F., N.M.S.), Texas Children's Hospital, Houston; Department of Neurology (T.L.S.), Children's Hospital Colorado, Aurora; Department of Neurology (S.S.M.), Washington University in St. Louis, MO; Department of Neurology (E. Waubant, A.V.), UCSF Weill Institute for Neurosciences, University of California San Francisco; and Department of Neurology (Y.S.W., J.M.N.), University of Alabama at Birmingham.
Lancet Diabetes Endocrinol
October 2024
Cardiovascular Clinical Research Center, NYU Grossman School of Medicine, New York, NY, USA.
Background: Patients hospitalised for COVID-19 are at risk for multiorgan failure and death. Sodium-glucose co-transporter-2 (SGLT2) inhibitors provide cardiovascular and kidney protection in patients with cardiometabolic conditions and could provide organ protection during COVID-19. We aimed to investigate whether SGLT2 inhibitors can reduce the need for organ support in patients hospitalised for COVID-19.
View Article and Find Full Text PDFAlzheimers Dement
October 2024
Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, Devon, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!